Puma Biotechnology (PBYI) Change in Accured Expenses (2011 - 2026)

Puma Biotechnology's Change in Accured Expenses history runs 16 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 18.34% year-over-year to -$11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.3 million (up 206.0% YoY) and the FY2025 annual result came in at $13.2 million, up 183.13% from the prior year.
• Change in Accured Expenses was -$11.7 million for Q1 2026 at Puma Biotechnology, down from $12.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $20.7 million in Q4 2022 and bottomed at -$30.9 million in Q1 2022.
• A 5-year average of -$3.2 million and a median of -$1.6 million in 2023 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 1283.49% in 2022, while the deepest fall reached 371.28% in 2022.
• Puma Biotechnology's Change in Accured Expenses stood at $20.7 million in 2022, then sank by 45.26% to $11.3 million in 2023, then plunged by 221.48% to -$13.8 million in 2024, then surged by 193.54% to $12.9 million in 2025, then tumbled by 190.83% to -$11.7 million in 2026.
• Business Quant data shows PBYI's Change in Accured Expenses at -$11.7 million in Q1 2026, $12.9 million in Q4 2025, and $5.3 million in Q3 2025.